SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Bob Rudd who wrote (14652)10/3/2002 11:27:52 AM
From: Bob Rudd  Read Replies (3) | Respond to of 78750
 
Added to losers 10/2 PLCM & SGP:
Former is leader in Video Conferencing, a business I still believe has substantial potential to replace travel due to corporate budget constraints and increasing hassles/time cost of air travel. PLCM has $3 a share in cash. Recent results are impacted by transition away from reselling stocking to direct distribution of physical product with resellers acting more as sales/service agents...this process results in end user demand being under-reflected in revenues as reseller's inventory is liquidated.
SGP 2 data points:
>>10/2/02 1:29 pm ET Schering-Plough falls to another new low (SGP) 18.28 -1.52: Stock continues to trade defensively -- hitting a new 52-wk low for second day in a row. Reuters is reporting that fund managers are blaming weakness on possibility that Q3 earnings estimates may be too high. We are hearing that contributing to weakness are concerns that co's cholesterol treatment Zetia may fail to secure sought after labeling... Volume today is 15.2 mln, or almost 3x average daily turnover.

10/2 Since Merck owns half the potential profits from Zetia, you would think they would be down too, if this rumor is out there, instead of being up over a dollar a share
I think selling is overdone, but I thought that at higher levels on both these...fortunately my initial positions were small and so were today's adds.